Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases that require medical intervention. Its lead product, YCANTH (cantharidin) topical solution 0.7%, became the first FDA-approved treatment for molluscum contagiosum in patients as young as two, a contagious viral skin infection affecting about six million people in the United States, primarily children. Verrica is commercializing YCANTH for molluscum, developing it for common warts, and advancing VP-315 for dermatologic oncology including basal cell and squamous cell carcinomas under a worldwide license with Lytix Biopharma.